Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors: Shaping the Future After the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial
Metabolism: Clinical and Experimental - Netherlands
doi 10.1016/j.metabol.2017.04.007
Full Text
Open PDFAbstract
Available in full text
Date
September 1, 2017
Authors
Publisher
Elsevier BV